CORT
Corcept Therapeutics Incorporated
117.50$
+3.3%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | +487.6% | +231.3% | +89.8% | +17.7% | +11.6% | +10.5% | -28.3% | +5.6% | +55.9% | -28.3% | |
| – | +9.9% | -43.9% | +21.8% | +122.6% | +819.9% | +3.0% | +37.1% | +12.4% | -31.5% | -43.4% | +41.5% | |
| – | +15.6% | +17.4% | +89.3% | +77.7% | +23.4% | +14.4% | +28.0% | -1.1% | +15.3% | +25.4% | +37.7% | |
| – | +15.6% | +17.4% | -993.3% | – | +22.2% | +3.4% | -1.0% | -79.0% | – | – | – | |
| – | – | +131.2% | -594.3% | – | -219.4% | – | – | – | +48.4% | +451.2% | -160.9% | |
| – | -90.2% | +1,041.2% | +116.0% | -28.9% | +265.1% | +13.8% | -62.1% | -11.9% | -66.3% | +1,462.6% | -90.3% | |
| – | -90.2% | +1,041.2% | +37,763.9% | +23.6% | +29.8% | +1.2% | – | -184.0% | – | -295.4% | – | |
| – | – | – | – | – | – | +209.2% | -34.1% | +68.0% | – | – | – | |
| – | +1,153.9% | -65.5% | -6.5% | -429.4% | +30.9% | -67.9% | +2,876.2% | -92.7% | +571.3% | -89.2% | +1,469.6% | |
| – | +89.6% | +60.5% | +2.4% | – | – | – | – | – | – | – | – | |
| – | – | -154.3% | +12.1% | +80.2% | +99.8% | – | -2,577.4% | -94.3% | +760.5% | -80.9% | +677.3% | |
| – | – | -31.4% | -284.4% | – | -198.0% | – | -96.8% | -891.0% | – | -111.4% | – | |
| – | – | +484.5% | +232.6% | +90.6% | +17.0% | +11.6% | +11.1% | -28.4% | +5.8% | +54.4% | -27.6% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.